Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications ; volume:26 ; number:1 ; day:15 ; month:2 ; year:2024 ; pages:1-13 ; date:12.2024
Breast cancer research ; 26, Heft 1 (15.2.2024), 1-13, 12.2024
- Creator
-
Scheffges, Claire
Devy, Jérôme
Giustiniani, Jérôme
Francois, Stessy
Cartier, Lucille
Merrouche, Yacine
Foussat, Arnaud
Potteaux, Stéphane
Bensussan, Armand
Marie-Cardine, Anne
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13058-024-01785-x
- URN
-
urn:nbn:de:101:1-2404230756262.867021483014
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Scheffges, Claire
- Devy, Jérôme
- Giustiniani, Jérôme
- Francois, Stessy
- Cartier, Lucille
- Merrouche, Yacine
- Foussat, Arnaud
- Potteaux, Stéphane
- Bensussan, Armand
- Marie-Cardine, Anne
- SpringerLink (Online service)
Other Objects (12)
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
Aberrant expression and potential therapeutic target of lysophosphatidic acid receptor 3 in triple-negative breast cancers
Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers
Emerging therapeutic agents for genitourinary cancers
Specific delivery of therapeutic agents against cancers
Specific delivery of therapeutic agents against cancers
Classification of triple-negative breast cancers based on Immunogenomic profiling
Targeting a cell state common to triple‐negative breast cancers
Melatonin and urological cancers: a new therapeutic approach
Hypoxia and its therapeutic possibilities in paediatric cancers
Evaluation of SSEA-4 as a CAR T cell therapeutic target for the treatment of chemoresistant triple negative breast cancers
Childhood cancers: what is a possible role of infectious agents?
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
Aberrant expression and potential therapeutic target of lysophosphatidic acid receptor 3 in triple-negative breast cancers
Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers
Emerging therapeutic agents for genitourinary cancers
Specific delivery of therapeutic agents against cancers
Specific delivery of therapeutic agents against cancers
Classification of triple-negative breast cancers based on Immunogenomic profiling
Targeting a cell state common to triple‐negative breast cancers
Melatonin and urological cancers: a new therapeutic approach
Hypoxia and its therapeutic possibilities in paediatric cancers
Evaluation of SSEA-4 as a CAR T cell therapeutic target for the treatment of chemoresistant triple negative breast cancers
Childhood cancers: what is a possible role of infectious agents?
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
Aberrant expression and potential therapeutic target of lysophosphatidic acid receptor 3 in triple-negative breast cancers
Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers
Emerging therapeutic agents for genitourinary cancers
Specific delivery of therapeutic agents against cancers
Specific delivery of therapeutic agents against cancers
Classification of triple-negative breast cancers based on Immunogenomic profiling
Targeting a cell state common to triple‐negative breast cancers
Melatonin and urological cancers: a new therapeutic approach
Hypoxia and its therapeutic possibilities in paediatric cancers
Evaluation of SSEA-4 as a CAR T cell therapeutic target for the treatment of chemoresistant triple negative breast cancers